 DUBLIN, Ohio--BUSINESS WIRE--Navidea Biopharmaceuticals, Inc. NYSE American: NAVB Navidea or the Company, a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and full year for the period ended December 31, 2020. We are very excited about the progress we have made, completing all the patients in the Phase 2B NAV3-31 trial and submitting our briefing book to the FDA were milestone 